Online Pharmacies Reviews & Ratings & Scam Reports

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 0-9

Located in: All Online Pharmacies Reviews And Ratings

myxelodaemails.com review

'.$fname.' reviews PharmaciesReview.com: myxelodaemails.com review - PharmaciesReview.com looks for evidence that myxelodaemails.com are following online pharmacy laws and practice standards. If you do want to buy from an myxelodaemails.com and you are sure that the myxelodaemails.com is legitimate, there are still a few precautions you should take. Make sure you know exactly how much the order will cost, including delivery fees and any currency conversion rates. Also make sure you know how to get a refund if the product does not arrive, is damaged or not what you ordered. Use Top rated online pharmacies reviews: Generic pharmacies reviews, Canadian pharmacies reviews, Mexican pharmacies reviews, US & UK pharmacies reviews, Indian pharmacies reviews, ED pharmacies reviews.

Pharmacy title	Metastatic Breast Cancer, Metastatic Colorectal Cancer, and Adjuvant Colon Cancer Treatment \| XELODA® (capecitabine)
Website	http://www.myxelodaemails.com
Reviews	0
Votes	0
Pharmacy description	Official Site for XELODA(R) (capecitabine) tablets for the treatment of metastatic colorectal and breast cancer as well as adjuvant colon cancer treatment. Learn more about XELODA (capecitabine)(R) oral chemotherapy medicine. XELODA is indicated as a single agent for adjuvant treatment in patients with Dukes' C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. XELODA was non-inferior to 5-fluorouracil and leucovorin (5-FU/LV) for disease-free survival (DFS). Physicians should consider results of combination chemotherapy trials, which have shown improvement in DFS and OS, when prescribing single-agent XELODA in the adjuvant treatment of Dukes' C colon cancer. XELODA is indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. Combination chemotherapy has shown a survival benefit compared to 5-FU/LV alone. A survival benefit over 5-FU/LV has not been demonstrated with XELODA monotherapy. Use of XELODA instead of 5-FU/LV in combinations has not been adequately studied to assure safety or preservation of the survival advantage. XELODA monotherapy is indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated, eg, patients who have received cumulative doses of 400 mg/m2 of doxorubicin or doxorubicin equivalents. Resistance is defined as progressive disease while on treatment, with or without an initial response, or relapse within 6 months of completing treatment with an anthracycline-containing adjuvant regimen. XELODA in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. Boxed WARNING and Contraindications Patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulants such as warfarin and phenprocoumon should have their anticoagulant response (INR or prothrombin time) monitored frequently in order to adjust the anticoagulant dose accordingly. Altered coagulation parameters and/or bleeding, including death, have been reported during concomitant use. XELODA is contraindicated in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency, severe renal impairment, or known hypersensitivity to capecitabine or to any of its components or to 5-fluorouracil. Additional Serious Adverse Reactions Additional serious adverse reactions include diarrhea, cardiotoxicity, hand-and-foot syndrome, and hyperbilirubinemia. XELODA can cause fetal harm. Advise women of the potential risk to the fetus. Do not treat patients with neutrophil counts =30%) were diarrhea, hand-and-foot syndrome, nausea, vomiting, abdominal pain, fatigue/weakness, and hyperbilirubinemia. Other adverse reactions, have been reported. Important safety information - Monotherapy in Adjuvant Colon Cancer In a phase 3 study of XELODA monotherapy in colon cancer in the adjuvant setting, serious adverse events (grade 3/4) occurring in >=5% of patients receiving either XELODA or 5FU/LV (%;%) were increase in bilirubin (20;6), hand-foot syndrome (17;=5% of patients receiving either XELODA or 5FU/LV (%;%) were hyperbilirubinemia (23;6), hand-foot syndrome (17;1), diarrhea (15;12), abdominal pain (=5% of patients receiving XELODA (%) were lymphopenia (59), diarrhea (15), hand-foot syndrome (11), hyperbilirubinemia (11), fatigue (8), stomatitis (7), and dehydration (5). Important safety information - Combination Therapy with Docetaxel in MBC In a phase 3 study of XELODA combination therapy (XELODA plus docetaxel) in metastatic breast cancer, serious adverse events (grade 3/4) occurring at a >=2% higher incidence in patients receiving XELODA plus docetaxel vs. docetaxel alone (%;%) were lymphocytopenia (89;84), hand-foot syndrome (24;1), stomatitis (
Screenshot of myxelodaemails.com has been captured on Jun-26-2012

Country	United States, USA (US)
City	South San Francisco
Online pharmacy myxelodaemails.com on the map

Online pharmacy myxelodaemails.com coupons and discount codes
Coupons	No data available at coupon
Discount codes	No data available at discount code

Rate now:

The information on this website, including information about online pharmacies, news, data and other information, is based on information from publicly available sources and information obtained by PharmaciesReview.com, PRC ('PHARMACIESREVIEW'). The information is intended solely for the personal use of the website user. PHARMACIESREVIEW EXPRESSLY DISCLAIMS ALL WARRANTIES, EXPRESSED OR IMPLIED, AS TO THE ACCURACY OF ANY THE CONTENT PROVIDED, OR AS TO THE FITNESS OF THE INFORMATION FOR ANY PURPOSE.

Furthermore, PharmaciesReview is not a government agency, law enforcement entity or regulatory authority. Information that a pharmacy website does not meet PharmaciesReview standards should not be taken to mean that a pharmacy or a website, or individuals associated with the pharmacy or the website, have violated any provision of state or federal law, or any state or federal regulation. Additionally, PharmaciesReview makes best efforts to ensure that our information about online pharmacies is timely and to re-review online pharmacies on a periodic basis, however, PharmaciesReview may not be aware of changes made to a website following our review of that website. Rather, PharmaciesReview simply represents that, at the time that PharmaciesReview reviewed the online pharmacy, available information indicated that the online pharmacy met or did not meet our standards as represented on this website.

PharmaciesReview.com does not provide medical advice nor recommendations regarding the use of any medicine, including prescription drugs. We do not request personal information in any unsolicited email correspondence with our customers. PharmaciesReview shall not be liable for any errors, inaccuracies or delays in content, or for any actions taken in reliance thereon. Although PharmaciesReview makes reasonable efforts to verify publicly available information and to obtain reliable content from third parties, PharmaciesReview does not guarantee the accuracy of or endorse the information or opinions given by any third party content provider. PharmaciesReview does not endorse or take responsibility for the content other sites that PharmaciesReview may link to or provide information about.